Qiagen NV (NYSE:QGEN)
$ 46.08 -0.08 (-0.17%) Market Cap: 10.26 Bil Enterprise Value: 10.70 Bil PE Ratio: 113.42 PB Ratio: 2.91 GF Score: 87/100

Qiagen NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 02:10PM GMT
Release Date Price: $54.6 (+0.76%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

Okay. Good morning, I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce our next company this morning, QIAGEN. Just a reminder for those that have questions to submit them through the website.

And with that, I'll turn it over to Thierry.

Thierry Bernard
QIAGEN N.V. - CEO, MD & Member of Management Board

Thank you so much, Tycho, and good morning, good afternoon, and good evening to all of you. Happy New Year on behalf for QIAGEN. So my name is Thierry Bernard, and my agenda today is to show you that we believe that QIAGEN emerged from 2020 as an independent, stronger and more focused company for the coming years, ready to execute on significant growth post-pandemic.

Moving to Slide 3, let me remind you who we are in a nutshell. The 5,300 QIAGENers all over the world are developing for more than 20 years now, cutting-edge solutions in Molecular Biology, both for life science and clinical applications.

At the last officially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot